Completed
Low Dose Oral Interferon Alfa-n3 for HIV+ Treatment
What is being tested
Interferon alfa-n3
Drug
Who is being recruted
Blood-Borne Infections+11
+ Urogenital Diseases
+ Genital Diseases
Over 18 Years
+26 Eligibility Criteria
How is the trial designed
Treatment Study
Interventional
Summary
Principal SponsorInterferon Sciences
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
This study focuses on HIV+ individuals who experience symptoms. It's testing a new treatment approach using a low dose of an immunomodulator called Alferon LDO, which is a form of Interferon Alfa-n3. The goal is to see if this oral medication can help manage HIV symptoms. This research is important because it could potentially offer a new treatment option for HIV+ patients, improving their quality of life and addressing unmet needs in HIV care.
Principal SponsorInterferon Sciences
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
60 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsHIV Infections
Criteria
4 inclusion criteria required to participate
At least 1 of the HIV-related clinical symptoms or opportunistic infections listed in protocol
If already on zidovudine (AZT) or didanosine (ddI), must have been on this therapy for at least 75 of the 90 days prior to study entry
Seropositivity to HIV-1 by ELISA and Western blot
Written informed consent
22 exclusion criteria prevent from participating
Active intravenous (IV) drug abuse
Asymptomatic at study entry
BCG vaccine within 45 days of study entry
Chemotherapy within 45 days of study entry
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
CompletedOne Study Center